Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Gross Margin (2016 - 2025)

Historic Gross Margin for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 79.89%.

  • Astrazeneca's Gross Margin fell 18100.0% to 79.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 81.9%, marking a year-over-year increase of 7700.0%. This contributed to the annual value of 81.9% for FY2025, which is 7700.0% up from last year.
  • Astrazeneca's Gross Margin amounted to 79.89% in Q4 2025, which was down 18100.0% from 81.56% recorded in Q3 2025.
  • Astrazeneca's Gross Margin's 5-year high stood at 5257.59% during Q4 2022, with a 5-year trough of 61.49% in Q4 2021.
  • In the last 5 years, Astrazeneca's Gross Margin had a median value of 81.74% in 2023 and averaged 706.48%.
  • As far as peak fluctuations go, Astrazeneca's Gross Margin skyrocketed by 51961000bps in 2022, and later plummeted by -51767900bps in 2023.
  • Astrazeneca's Gross Margin (Quarter) stood at 61.49% in 2021, then skyrocketed by 8450bps to 5257.59% in 2022, then tumbled by -98bps to 80.81% in 2023, then grew by 1bps to 81.7% in 2024, then decreased by -2bps to 79.89% in 2025.
  • Its Gross Margin stands at 79.89% for Q4 2025, versus 81.56% for Q3 2025 and 82.89% for Q2 2025.